• Blog
  • News
During a challenging year, M&A activity in pharmaceutical markets was lower than experts estimated. Also, there were not many megadeals in Q1 and Q2 compared with 2019 (where the value of the largest deal was $99.5 billion). The biggest deals in the first half of 2020 were Thermo Fisher Scientific / Qiagen ($11.5 billion, COVID-19), Gilead Sciences / Forty Seven ($4.9 billion, oncology), Gilead Sciences / Pionyr Immunotherapeutics ($1.7 billion, oncology), Novo Nordisk / Corvidia ($2.1 billion, cardiometabolic diseases), Eli Lilly / Dermira ($1.1 billion, immunology, dermatology).
Expert at the BRICS Competition Centre
The Federal Antimonopoly Service of Russia plans to initiate a case for the sale of express tests for coronavirus to the population in retail chains, testing for COVID-19 should be carried out by specialists, said the head of the department Igor Artemyev.
The General Superintendence of the Administrative Council for Economic Defense sent the merger act for analysis by the autarchy court regarding the acquisition, by the pharmaceutical company Hypera, of the development, manufacture, marketing, distribution and sale of the Buscopan product family in Brazil - currently owned by Boehringer Ingelheim International.
FAS Russia Deputy Head Andrey Tsyganov spoke about the activities of the antimonopoly service during the COVID-19 crisis and discussed the development of competition with experts and representatives of Russian companies
The Competition Commission of South Africa has announced that it welcomes the decision of the Competition Tribunal that confirms the settlement agreement between the Commission and Cape Town-based company - Caprichem.
The Administrative Council for Economic Defense has published a brief information note in which it deals with the collaboration between companies in the face of the Covid-19 crisis. The document provides guidance on the parameters recommended in the elaboration of strategies to combat the pandemic and on the procedures available for economic agents to obtain CADE's statement.
The issues of price regulation for vital medicines remains a heated issue for all participants in the healthcare system especially when it comes to the mechanisms that are necessary to ensure the presence of drugs on the pharmaceutical market.
Competition Authorities’ approaches to global economic concentration: How to respond jointly to the challenges of a growing global pharmaceutical oligopoly?
Advocate General of the European Court of Justice, Juliane Kokott expressed the view that the judicial authority should support the decision of UK Competition and Market Authority that transactions to delay the entry into the market of generics (pay-for-delay) between GlaxoSmithKline and other companies are in violation of antitrust laws, FirstWord Pharma reports.
The Federal Antimonopoly Service (FAS) of Russia has recorded complaints from citizens about the rise in the price of several products amid a decline in imports from China due to coronavirus. Mr Andrey Tsyganov, the deputy head of the FAS Russia has commented on the situation with the following statement - "We see reports about prices rising for some products, but not from reports of our territorial administrations, but the media and citizens".
In the interview to The Wall Street Journal, Assistant Attorney General Makan Delrahim said that the Justice Department is preparing to research and investigate the generic drug industry and even go as far as filing cases for allegedly fixing prices. The department has been investigating possible criminal conduct by generic drug companies for years, but there has been little action so far.
In July 2019 the head of the Federal Antimonopoly Service Igor Artemiev at a meeting with Russian President Vladimir Putin said that in Russia, the problem of cartels is now most acute in the pharmaceutical industry. Three months later, we can see the progress in the battle with the cartels
The second day of the BRICS International Competition Conference has not only started with a varietal topic but was also concluded with another life and death importance level panel – pharmaceutical regulation. The issues that could be discussed within this area are vast; however, most of the representatives from BRICS competition authorities have focused on two common problems for all of the countries – generics and pricing.
Roundtable “Anticompetitive practices of the Big Pharma: response of the BRICS Competition Authorities” took place on September 25 within the framework of  the International Russia Competition Week
During Competition Week, on September 25, Alexey Ivanov acted as a moderator of the discussion held within the framework of the Working Group on the study of competition problems in pharmaceutical markets.
On March 24 at the World Trade Centre a joint meeting of the International Working Group on the research of competition issues in the pharmaceutical sector was held, with the Federal Antimonopoly Service of Russia, with a high-level panel discussion on: "the Experience of the BRICS countries in overcoming the HIV/AIDS epidemic: the availability of medicines".
On the 22-23rd June the BRICS Competition Law and Policy Forum took place at HSE St Petersburg. The international conference was organised jointly by the HSE-Skolkovo Institute for Law and Development, the Centre for Law, Economics and Society at UCL and the Russian Federal Antimonopoly Service (FAS). Heads of antitrust departments and experts from the BRICS and the EEC were joined by leading academics and experts on competition law from Europe and the US.